New Alzheimer's blood test could be available on NHS within next five years

Blood tests for Alzheimer’s could be available on the National Health Service within five years, experts have said.

A new £5 million ($6.1 million) project between Alzheimer’s Research UK and the Alzheimer’s Society will bring simple tests to the NHS with the hope of speeding up diagnosis and reaching more people.

Currently, diagnosing people with Alzheimer’s can be tricky and relies on brain imaging or painful lumbar punctures, in which a sample of cerebrospinal fluid is drawn from the lower back.

Less than two thirds of people in England with dementia have a formal diagnosis and many can face long waits to be seen.

Using £5 million of funding from the People’s Postcode Lottery, the charities are now working with the National Institute for Health and Care Research to make blood tests on the NHS a reality.

A range of tests for Alzheimer’s are in the research stages, including those looking for specific proteins that occur before dementia symptoms appear.

Pharmaceutical companies Roche and Eli Lilly have also announced they have joined forces to develop a blood test for Alzheimer’s disease.

Some tests were already being used in private clinics in Hong Kong and the US, but UK charities said more work was needed to ensure tests were measuring the right combination of biomarkers.

The need for blood tests to diagnose Alzheimer’s has become more pressing since the medicines donanemab and lecanemab were found to slow cognitive decline.

Both these drugs made headlines around the world and are set to be assessed for use in the UK.

How a three-minute iPad test could diagnose dementia – video

“We expect more people to be coming forward for diagnosis, we expect them to be coming forward at a younger age and we expect them to be coming forward with less obvious symptoms,” Susan Kohlhaas, executive director of research and partnerships at Alzheimer’s Research UK, told a briefing.

“We need better, more scalable tests that are also accurate, and compare to current gold-standard methods.

“We’re sitting on the cusp of a new era of dementia treatments” but “the NHS doesn’t possess the required levels of diagnostic infrastructure to cope with this growing demand.

“Currently, only 2 per cent of people are offered advanced diagnostic tests like PET scans and lumbar punctures.

“Significant investment is needed to ensure the NHS has the right tools to identify people with dementia much earlier than it is currently able to.

“Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold-standard methods are the answer to this.

“But we need to move these tests out of the lab and assess their effectiveness in real-world settings like the NHS.”

The new project – the Blood Biomarker Challenge – will work with researchers to pilot new blood tests in the NHS that can diagnose different forms of dementia earlier and more accurately.

There is no suggestion as yet that the tests could be used for mass population testing.

“New drugs targeting early stage Alzheimer’s disease are just around the corner, but without a diagnosis, people simply won’t be able to access them if they are approved,” said Fiona Carragher, director of research and influencing at the Alzheimer’s Society.

She said introducing a blood test for dementia into UK healthcare systems would be “a truly game-changing win in the fight against this devastating disease”.

Dementia affects about 900,000 people in the UK and experts predict that will rise to 1.4 million by 2040.

“The NHS welcomes this further research which could develop simpler tests for Alzheimer’s, while the health service as a world-leader in rolling out innovative treatments has set up a dedicated programme to prepare for the arrival of new treatments once they are approved by regulators, and this includes assessing additional testing requirements,” said Claire Murdoch, NHS England’s national mental health director.

“NHS staff have also worked hard to increase dementia diagnosis rates to their highest level in three years, following the pandemic when people were less likely to come forward for care.”